1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Europe Virus-like Particles Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Europe Virus-like Particles Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Europe Virus-like Particles Market Regional Analysis
6.2 Europe Virus-like Particles Market Revenue 2019-2028 (US$ Million)
6.3 Europe Virus-like Particles Market Forecast Analysis
7. Europe Virus-like Particles Market Analysis – by Product Type
7.1 Hepatitis
- 7.1.1 Overview
- 7.1.2 Hepatitis: Europe Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.2 Cancer/HPV
- 7.2.1 Overview
- 7.2.2 Cancer/HPV: Europe Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)
7.3 Gaucher disease
- 7.3.1 Overview
- 7.3.2 Gaucher disease: Europe Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)
8. Europe Virus-like Particles Market Analysis – by Source
8.1 Yeast
- 8.1.1 Overview
- 8.1.2 Yeast: Europe Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.2 Insect Cell
- 8.2.1 Overview
- 8.2.2 Insect Cell: Europe Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)
8.3 Plant
- 8.3.1 Overview
- 8.3.2 Plant: Europe Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)
9. Europe Virus-like Particles Market Analysis – by Application
9.1 Vaccines and Therapeutics
- 9.1.1 Overview
- 9.1.2 Vaccines and Therapeutics : Europe Virus-like Particles Market – Revenue and Forecast, 2019-2028 (US$ Million)
10. Europe Virus-like Particles Market – Europe Analysis
10.1 Overview
10.2 Europe
- 10.2.1 Europe Virus-like Particles Market Breakdown, by Key
Country, 2022 and 2028 (%)
- 10.2.1.1 Europe Virus-like Particles Market – Revenue and
Forecast Analysis – by Country
- 10.2.1.1 UK:
Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.1.1 UK: Europe Virus-like Particles Market Breakdown, by Product Type
- 10.2.1.1.2 UK: Europe Virus-like Particles Market Breakdown, by Source
- 10.2.1.1.3 UK: Europe Virus-like Particles Market Breakdown, by Application
- 10.2.1.2 Germany:
Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.2.1 Germany: Europe Virus-like Particles Market Breakdown, by Product Type
- 10.2.1.2.2 Germany: Europe Virus-like Particles Market Breakdown, by Source
- 10.2.1.2.3 Germany: Europe Virus-like Particles Market Breakdown, by Application
- 10.2.1.3 France:
Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.3.1 France: Europe Virus-like Particles Market Breakdown, by Product Type
- 10.2.1.3.2 France: Europe Virus-like Particles Market Breakdown, by Source
- 10.2.1.3.3 France: Europe Virus-like Particles Market Breakdown, by Application
- 10.2.1.4 Russia:
Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.4.1 Russia: Europe Virus-like Particles Market Breakdown, by Product Type
- 10.2.1.4.2 Russia: Europe Virus-like Particles Market Breakdown, by Source
- 10.2.1.4.3 Russia: Europe Virus-like Particles Market Breakdown, by Application
- 10.2.1.5 Italy:
Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.5.1 Italy: Europe Virus-like Particles Market Breakdown, by Product Type
- 10.2.1.5.2 Italy: Europe Virus-like Particles Market Breakdown, by Source
- 10.2.1.5.3 Italy: Europe Virus-like Particles Market Breakdown, by Application
- 10.2.1.6 Rest of Europe:
Europe Virus-like Particles Market – Revenue and Forecast to 2028 (US$ Million)
- 10.2.1.6.1 Rest of Europe: Europe Virus-like Particles Market Breakdown, by Product Type
- 10.2.1.6.2 Rest of Europe: Europe Virus-like Particles Market Breakdown, by Source
- 10.2.1.6.3 Rest of Europe: Europe Virus-like Particles Market Breakdown, by Application
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Industry Landscape
12.1 Overview
12.2 Market Initiative
12.3 Partnerships and Collaborations
12.4 Other Developments
13. Company Profiles
13.1 Merck & Co., Inc.
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 GlaxoSmithKline plc.
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Pfizer Inc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Sanofi
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Serum Institute of India Pvt. Ltd.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 BHARAT BIOTECH
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 LG Chem
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 Dynavax Technologies
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
14. Appendix
14.1 About Business Market Insights
14.2 List of Abbreviations